 Home > Medical News > Medical World News > Suoyuan Biotech's "first-in-class" new drug successfully achieved overseas authorization

Suoyuan Biotech's "first-in-class" new drug successfully achieved overseas authorization

 Last Update: 2021-05-02
 Source: Internet
 Author: User

Tags

therapy

disease

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Source: Guanlan Pharmaceutical

On April 14, Suoyuan Biopharmaceuticals and Rumpus Therapeutics/Aytu Biopharma signed a global license agreement for the development of DB102 (enzastaurin) for the treatment of vascular Ehlers-Danglos syndrome (vEDS) and other rare genetic diseases.

vEDS is a rare genetic disease and a severe subtype of Ehlers-Danlos syndrome.

DB102 was originally developed by Eli Lilly and Company for the first-line treatment of newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL) and glioblastoma (GBM).

Note: The original text has been deleted

▽ attention [drug Mingkang Germany ] micro-channel public number

[Medical attention Mingkang Germany ] ] micro-channel public number

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.